Drug development translational research

Lee, J.W., Figeys, D., and Vasilescu, J. (2007) Biomarker assay translation from discovery to clinical studies in cancer drug development quantification of emerging protein biomarkers. In Sikora, K. (ed.), Genomics in Cancer Drug Discovery and Development. Advances in Cancer Research Hampton GM, Elsevier, pp. 269 298. 

Sanchez-Serrano, I. Success in translational research Lessons from the development of bortezomib. Nat. Rev. Drug Discov. 2006, 5, 107. This article provides a fascinating introduction to the unexpected paths from concept to market that drugs can take in the real world. 

In conclusion, the supply of pure, natively folded chemokine proteins is vital for a variety of basic, translation and cHnical research programs. Our structure-function studies and drug development efforts have motivated the development of the robust protocol for recombinant chemokine expression, refolding, purification, and vahdation presented here. Finally, many additional factors must be considered when manufacturing a product under cGMP guidehnes that may not be obvious to personnel in research settings. 

One of the primary strengths of the PROTAC technique as compared to other known methods for post-translational protein degradation is the fact that no biochemical manipulations are required for activity. Other techniques require the creation of fusion proteins, which is not only time-consuming within the context of laboratory research, but also precludes their use in a clinical situation. While the proof-of-concept PROTAC experiments described in this chapter often utilized a GFP-target protein fusion, this was done simply for visualization purposes, and is not required for PROTAC activity. The fact that a PROTAC could potentially be exogenously administered to any cell type or organism and exert its full effect makes the technique a viable option for drug development. 

Although there is a clear increasing trend in research regarding the development of PCL materials for drug delivery and implantation devices, an obvious gap exists between the number of these researched potential implants and the number of actually commercialised materials. Until now, this fact was attributed to lack of suBicient finances or infrastructure to ensure a proper translational research (Woodruff and Hutmacher, 2010). Following the prospects on the polymer market and the number of increased research projects, one can only assume that, from now on, there is an ascending trend towards a better valorisation of PCL and PCL-based biomaterials. 

---